{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:57:12Z","timestamp":1791464232262,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca and Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15537-3","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:50:32Z","timestamp":1770202232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Homologous recombination deficiency in newly diagnosed advanced ovarian cancer across nine Middle East countries: prevalence, real-world testing pathways, and treatment implications"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-9578","authenticated-orcid":false,"given":"Emad","family":"Shash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehemet Ali","family":"Vardar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagatay","family":"Taskiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salha","family":"Boujassoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Riromar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aboutaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Samy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Bahaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"15537_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00432-025-06277-9","volume":"151","author":"Y Ren","year":"2025","unstructured":"Ren Y, Xu R, Wang Y, Su L, Su J. Global, regional, and National burden of ovarian cancer in women aged 45\u2009+\u2009from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 global burden of disease study. J Cancer Res Clin Oncol. 2025;151:225. https:\/\/doi.org\/10.1007\/s00432-025-06277-9.","journal-title":"J Cancer Res Clin Oncol"},{"key":"15537_CR2","doi-asserted-by":"publisher","first-page":"e2300393","DOI":"10.1200\/GO.23.00393","volume":"10","author":"M Wang","year":"2024","unstructured":"Wang M, Bi Y, Jin Y, Zheng Z-J. Global incidence of ovarian cancer according to histologic subtype: A Population-Based cancer registry study. JCO Glob Oncol. 2024;10:e2300393. https:\/\/doi.org\/10.1200\/GO.23.00393.","journal-title":"JCO Glob Oncol"},{"key":"15537_CR3","volume-title":"Global cancer observatory: cancer today","author":"J Ferlay","year":"2024","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2024."},{"key":"15537_CR4","unstructured":"Global cancer observatory. Western Asia. 2022. Available at: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/922-western-asia-fact-sheet.pdf. Accessed on 9 September 2024."},{"key":"15537_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/cancers10110433","volume":"10","author":"J Kim","year":"2018","unstructured":"Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho C-H, et al. Cell origins of High-Grade serous ovarian cancer. Cancers (Basel). 2018;10:433. https:\/\/doi.org\/10.3390\/cancers10110433.","journal-title":"Cancers (Basel)"},{"key":"15537_CR6","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.3390\/cancers15123095","volume":"15","author":"ES Paik","year":"2023","unstructured":"Paik ES, Chang HK, Lee S. Prevalence of homologous recombination deficiency in First-Line PARP inhibitor maintenance clinical trials and further implication of personalized treatment in ovarian cancer. Cancers (Basel). 2023;15:3095. https:\/\/doi.org\/10.3390\/cancers15123095.","journal-title":"Cancers (Basel)"},{"key":"15537_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/cancers15010043","volume":"15","author":"G Magliacane","year":"2022","unstructured":"Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, et al. Locally performed HRD testing for ovarian cancer? Yes. We Can! Cancers (Basel). 2022;15:43. https:\/\/doi.org\/10.3390\/cancers15010043.","journal-title":"We Can! Cancers (Basel)"},{"key":"15537_CR8","doi-asserted-by":"publisher","unstructured":"da Cunha Colombo, Bonadio RR, Fogace RN, Miranda VC, Diz M. del PE. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics (Sao Paulo). 2018;73Suppl1:e450s. https:\/\/doi.org\/10.6061\/clinics\/2018\/e450s.","DOI":"10.6061\/clinics\/2018\/e450s"},{"key":"15537_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34:681\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005.","journal-title":"Ann Oncol"},{"key":"15537_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. Maintenance Olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:1721\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(21)00531-3.","journal-title":"Lancet Oncol"},{"key":"15537_CR11","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with First-Line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381:2403. https:\/\/doi.org\/10.1056\/NEJMoa1909707.","journal-title":"N Engl J Med"},{"key":"15537_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial\u2606. Ann Oncol. 2024;35:981\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2241.","journal-title":"Ann Oncol"},{"key":"15537_CR13","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","volume":"40","author":"BJ Monk","year":"2022","unstructured":"Monk BJ, Parkinson C, Lim MC, O\u2019Malley DM, Oaknin A, Wilson MK, et al. A Randomized, phase III trial to evaluate Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J Clin Oncol. 2022;40:3952\u201364. https:\/\/doi.org\/10.1200\/JCO.22.01003.","journal-title":"J Clin Oncol"},{"key":"15537_CR14","unstructured":"FDA approves olaparib. tablets for maintenance treatment in ovarian cancer https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer#:~:text=FDA%20approved%20olaparib%20capsules%20in,olaparib%20tablets%20for%20this%20indication."},{"key":"15537_CR15","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Name Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer V.3.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed [February 01, 2024]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"15537_CR16","doi-asserted-by":"publisher","unstructured":"Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen W-J, et al. Prevalence of homologous Recombination\u2013Related gene mutations across multiple cancer types. JCO Precision Oncol. 2018;2. https:\/\/doi.org\/10.1200\/PO.17.00286. PO.17.00286.","DOI":"10.1200\/PO.17.00286"},{"key":"15537_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/cas.15518","volume":"114","author":"K Oda","year":"2022","unstructured":"Oda K, Aoki D, Tsuda H, Nishihara H, Aoyama H, Inomata H, et al. Japanese nationwide observational multicenter study of tumor BRCA1\/2 variant testing in advanced ovarian cancer. Cancer Sci. 2022;114:271. https:\/\/doi.org\/10.1111\/cas.15518.","journal-title":"Cancer Sci"},{"key":"15537_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13048-023-01129-x","volume":"16","author":"Z Feng","year":"2023","unstructured":"Feng Z, Shao D, Cai Y, Bi R, Ju X, Chen D, et al. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. J Ovarian Res. 2023;16:53. https:\/\/doi.org\/10.1186\/s13048-023-01129-x.","journal-title":"J Ovarian Res"},{"key":"15537_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13073-021-01003-9","volume":"13","author":"AN Abou Tayoun","year":"2021","unstructured":"Abou Tayoun AN, Fakhro KA, Alsheikh-Ali A, Alkuraya FS. Genomic medicine in the middle East. Genome Med. 2021;13:184. https:\/\/doi.org\/10.1186\/s13073-021-01003-9.","journal-title":"Genome Med"},{"key":"15537_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.5306\/wjco.v15.i7.848","volume":"15","author":"N Syed","year":"2024","unstructured":"Syed N, Chintakuntlawar AV, Vilasini D, Al Salami AM, Al Hasan R, Afrooz I, et al. Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in middle East BRCA\/homologous recombination deficiency-positive cancer patients. World J Clin Oncol. 2024;15:848\u201358. https:\/\/doi.org\/10.5306\/wjco.v15.i7.848.","journal-title":"World J Clin Oncol"},{"key":"15537_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10549-017-4635-4","volume":"168","author":"A-J Alhuqail","year":"2018","unstructured":"Alhuqail A-J, Alzahrani A, Almubarak H, Al-Qadheeb S, Alghofaili L, Almoghrabi N, et al. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in Arab breast and ovarian cancer patients. Breast Cancer Res Treat. 2018;168:695\u2013702. https:\/\/doi.org\/10.1007\/s10549-017-4635-4.","journal-title":"Breast Cancer Res Treat"},{"key":"15537_CR22","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1186\/s12885-021-09094-8","volume":"21","author":"F Azribi","year":"2021","unstructured":"Azribi F, Abdou E, Dawoud E, Ashour M, Kamal A, Al Sayed M, et al. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study. BMC Cancer. 2021;21:1350. https:\/\/doi.org\/10.1186\/s12885-021-09094-8.","journal-title":"BMC Cancer"},{"key":"15537_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/humu.23736","volume":"40","author":"AK Siraj","year":"2019","unstructured":"Siraj AK, Bu R, Iqbal K, Siraj N, Al-Haqawi W, Al-Badawi IA, et al. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the middle East. Hum Mutat. 2019;40:729\u201333. https:\/\/doi.org\/10.1002\/humu.23736.","journal-title":"Hum Mutat"},{"key":"15537_CR24","doi-asserted-by":"publisher","unstructured":"Frontline Management of Advanced Epithelial Ovarian Cancer. A comprehensive statement by the Africa middle East cancer Inter-group [AMCI]. Curr Women\u2019s Health Reviews. 2024;20. https:\/\/doi.org\/10.2174\/1573404819666221021091708.","DOI":"10.2174\/1573404819666221021091708"},{"key":"15537_CR25","doi-asserted-by":"publisher","first-page":"1045739","DOI":"10.3389\/fpubh.2022.1045739","volume":"10","author":"MG Katoue","year":"2022","unstructured":"Katoue MG, Cerda AA, Garc\u00eda LY, Jakovljevic M. Healthcare system development in the middle East and North Africa region: Challenges, endeavors and prospective opportunities. Front Public Health. 2022;10:1045739. https:\/\/doi.org\/10.3389\/fpubh.2022.1045739.","journal-title":"Front Public Health"},{"key":"15537_CR26","doi-asserted-by":"crossref","unstructured":"Balkhi B, Alshayban D, Alotaibi NM. Impact of healthcare expenditures on healthcare outcomes in the middle East and North Africa (MENA) region: a crossc country comparison, 1995\u20132015. Front Public Health. 2021;8:624962.","DOI":"10.3389\/fpubh.2020.624962"},{"key":"15537_CR27","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297. https:\/\/doi.org\/10.1371\/journal.pmed.0040297.","journal-title":"PLoS Med"},{"key":"15537_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","volume":"26","author":"J Prat","year":"2015","unstructured":"Prat J, FIGO Committee on Gynecologic Oncology. FIGO\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26:87\u20139. https:\/\/doi.org\/10.3802\/jgo.2015.26.2.87.","journal-title":"J Gynecol Oncol"},{"key":"15537_CR29","doi-asserted-by":"publisher","unstructured":"Khokhlova S, Alnaqqash MA, Bahaj W, Bujassoum S, Lee J, Mokhtar M, et al. Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and\/or fallopian tube cancer: the international HALO study. Int J Gynecol Cancer. 2025;35. https:\/\/doi.org\/10.1016\/j.ijgc.2025.101645.","DOI":"10.1016\/j.ijgc.2025.101645"},{"key":"15537_CR30","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402. https:\/\/doi.org\/10.1056\/NEJMoa1910962.","journal-title":"N Engl J Med"},{"key":"15537_CR31","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1111\/cas.15747","volume":"114","author":"K Yoshihara","year":"2023","unstructured":"Yoshihara K, Baba T, Tokunaga H, Nishino K, Sekine M, Takamatsu S, et al. Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 study. Cancer Sci. 2023;114:2515\u201323. https:\/\/doi.org\/10.1111\/cas.15747.","journal-title":"Cancer Sci"},{"key":"15537_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12885-019-5463-1","volume":"19","author":"K Abdulrashid","year":"2019","unstructured":"Abdulrashid K, AlHussaini N, Ahmed W, Thalib L. Prevalence of BRCA mutations among hereditary breast and\/or ovarian cancer patients in Arab countries: systematic review and meta-analysis. BMC Cancer. 2019;19:256. https:\/\/doi.org\/10.1186\/s12885-019-5463-1.","journal-title":"BMC Cancer"},{"key":"15537_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.32074\/1591-951X-791","volume":"114","author":"C Fumagalli","year":"2022","unstructured":"Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, et al. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD focus panel with myriad mychoicecdx assay. Pathologica. 2022;114:288\u201394. https:\/\/doi.org\/10.32074\/1591-951X-791.","journal-title":"Pathologica"},{"key":"15537_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","volume":"35","author":"JA Ledermann","year":"2024","unstructured":"Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al. ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease\u2606. Ann Oncol. 2024;35:248\u201366. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.015.","journal-title":"Ann Oncol"},{"key":"15537_CR35","doi-asserted-by":"publisher","unstructured":"Esin E, Ahmed MA, Y\u0131ld\u0131r\u0131m H\u00c7, Mandel NM, Erdemoglu E, Sari M et al. Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program\u2014LynTurk study. JCO. 2023;41 16_suppl:e17509\u2013e17509. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e17509.","DOI":"10.1200\/JCO.2023.41.16_suppl.e17509"},{"key":"15537_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5583","author":"JCF Quintanilha","year":"2023","unstructured":"Quintanilha JCF, Graf R, Danziger N, Washington C, Dockery LE, Snow T, et al. Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1\/2 and HRD signature in real-world practice. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5583.","journal-title":"J Clin Oncol"},{"key":"15537_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12957-023-03027-4","volume":"21","author":"R Purwar","year":"2023","unstructured":"Purwar R, Ranjan R, Pal M, Upadhyay SK, Kumar T, Pandey M. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials. World J Surg Oncol. 2023;21:157. https:\/\/doi.org\/10.1186\/s12957-023-03027-4.","journal-title":"World J Surg Oncol"},{"key":"15537_CR38","doi-asserted-by":"publisher","first-page":"103433","DOI":"10.1016\/j.drudis.2022.103433","volume":"28","author":"MHE Callenbach","year":"2023","unstructured":"Callenbach MHE, \u00c1d\u00e1m lldik\u00f3, Vreman RA, N\u00e9meth B, Kal\u00f3 Z, Goettsch WG. Reimbursement and payment models in central and Eastern European as well as middle Eastern countries: A survey of their current use and future outlook. Drug Discovery Today. 2023;28:103433. https:\/\/doi.org\/10.1016\/j.drudis.2022.103433.","journal-title":"Drug Discovery Today"},{"key":"15537_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-981-99-6794-0_14","volume-title":"Cancer care in the united Arab Emirates","author":"FA Khan","year":"2024","unstructured":"Khan FA, El Khoury M. Genomic medicine in cancer care in the UAE. In: Al-Shamsi HO, editor. Cancer care in the united Arab Emirates. Singapore: Springer Nature; 2024. pp. 225\u201334. https:\/\/doi.org\/10.1007\/978-981-99-6794-0_14."},{"key":"15537_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1136\/ijgc-2022-003913","volume":"33","author":"BN Hughes","year":"2023","unstructured":"Hughes BN, Jorgensen KA, Cummings S, Morah D, Krause K, Rauh-Hain JA, et al. Systematic mapping review of guidelines for BRCA1\/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer. Int J Gynecol Cancer. 2023;33:250\u20136. https:\/\/doi.org\/10.1136\/ijgc-2022-003913.","journal-title":"Int J Gynecol Cancer"},{"key":"15537_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/jpm10040216","volume":"10","author":"AT Rahma","year":"2020","unstructured":"Rahma AT, Elsheik M, Ali BR, Elbarazi I, Patrinos GP, Ahmed LA, et al. Knowledge, Attitudes, and perceived barriers toward genetic testing and pharmacogenomics among healthcare workers in the united Arab emirates: A Cross-Sectional study. J Personalized Med. 2020;10:216. https:\/\/doi.org\/10.3390\/jpm10040216.","journal-title":"J Personalized Med"},{"key":"15537_CR42","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1002\/ijc.33493","volume":"148","author":"TN Bethea","year":"2021","unstructured":"Bethea TN, Ochs-Balcom HM, Bandera EV, Beeghly-Fadiel A, Camancho F, Chyn D, et al. First- and second-degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and white women. Int J Cancer. 2021;148:2964. https:\/\/doi.org\/10.1002\/ijc.33493.","journal-title":"Int J Cancer"},{"key":"15537_CR43","doi-asserted-by":"publisher","unstructured":"Epithelial Ovarian Cancer in Older Women. Defining the Best Management Approach | American Society of Clinical Oncology Educational Book. https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.e311. Accessed 19 Nov 2024.","DOI":"10.14694\/EdBook_AM.2015.35.e311"},{"key":"15537_CR44","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1002\/ijc.27952","volume":"132","author":"T-T Gong","year":"2012","unstructured":"Gong T-T, Wu Q-J, Vogtmann E, Lin B, Wang Y-L. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer J Int Du Cancer. 2012;132:2894. https:\/\/doi.org\/10.1002\/ijc.27952.","journal-title":"Int J Cancer J Int Du Cancer"},{"key":"15537_CR45","doi-asserted-by":"publisher","first-page":"80589","DOI":"10.18632\/oncotarget.20384","volume":"8","author":"F Shen","year":"2017","unstructured":"Shen F, Chen S, Gao Y, Dai X, Chen Q. The prevalence of malignant and borderline ovarian cancer in pre- and post-menopausal Chinese women. Oncotarget. 2017;8:80589. https:\/\/doi.org\/10.18632\/oncotarget.20384.","journal-title":"Oncotarget"},{"key":"15537_CR46","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jmoldx.2022.09.004","volume":"24","author":"C Denkert","year":"2022","unstructured":"Denkert C, Romey M, Swedlund B, Hattesohl A, Teply-Szymanski J, Kommoss S, et al. Homologous recombination deficiency as an ovarian cancer biomarker in a Real-World cohort: validation of decentralized genomic profiling. J Mol Diagn. 2022;24:1254\u201363. https:\/\/doi.org\/10.1016\/j.jmoldx.2022.09.004.","journal-title":"J Mol Diagn"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15537-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:43:01Z","timestamp":1771850581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15537-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15537"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15537-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol (ClinicalTrials.gov: NCT04991051) and all study documents were reviewed and approved prior to enrolment by the following independent ethics committees\/institutional review boards. Written informed consent was obtained from all participants (or next of kin\/legal representatives) before any study procedures. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and applicable local regulations.\u2022 Egypt:\u25e6 Research Ethics Committee for Human Subject Research, National Air Force Specialized Hospital, Cairo, Egypt\u25e6 Institutional Review Board, Faculty of Medicine, Alexandria University, Alexandria, Egypt\u25e6 Institutional Review Board, Faculty of Medicine, Assiut University, Assiut, Egypt\u25e6 Institutional Review Board, National Cancer Institute, Cairo University, Cairo, Egypt\u25e6 Institutional Review Board, Shifaa Al-Orman Hospital, Luxor, Egypt\u2022 Iraq: \u25e6Ministry of Health and Environment \u2013 The National Centre for Training and Human Development, Baghdad, Iraq\u2022 Jordan:\u25e6 King Hussein Cancer Center Institutional Review Board, Amman, Jordan\u2022 Saudi Arabia:\u25e6 Research and Innovation, King Abdullah Medical City in the Holy Capital (KAMC-HC), Makkah, Saudi Arabia\u25e6 Institutional Review Board, International Medical Center, Jeddah, Saudi Arabia\u2022 Turkey:\u25e6 \u00c7ukurova University Clinical Research Ethics Committee, Adana, Turkey\u2022 United Arab Emirates:\u25e6 Scientific Research Ethics Committee, Department of Health \u2013 Abu Dhabi, Abu Dhabi, UAE\u2022 Kuwait:\u25e6 Scientific Research and Ethics Committee, Ministry of Health, Kuwait\u2022 Oman:\u25e6 Scientific Research Committee, Royal Hospital, Muscat, Oman\u2022 Qatar:\u25e6 Hamad Medical Corporation Institutional Review Board, Doha, Qatar","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Emad Shash served in advisory or consultancy roles for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Clinart MENA, Genomics Genetics, GSK, Hikma, EVA Pharma, Janssen, Lilly, MSD, Mundipharma, Newbridge, Novartis, Pfizer, Pierre Fabre, and Roche. He received travel grants from Boehringer Ingelheim, Hikma, Janssen, Lilly, MSD, Mundipharma, Novartis, Pfizer, and Roche. He participated as an investigator in clinical trials sponsored by AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, and Roche. Dr Cagatay Taskiran, Dr. Jamila Riromar, Dr. Mehemet Ali Vardar, Dr. Salha Boujassoum, and Dr. Waleed Bahaj do not have any conflict of interest.Ahmed Aboutaleb, Eman Samy, and Farah Sadek are employees at AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}